Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer
- PMID: 21372743
- DOI: 10.1097/JTO.0b013e31820eed00
Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer
Abstract
Purpose: Combined modality therapy (CMT; radiation and chemotherapy) is indicated for fit, elderly patients with inoperable, locally advanced non-small cell lung cancer. We used population level data to examine effects of CMT on survival.
Methods: Medicare patients who are 66 years or older with locally advanced non-small cell lung cancer (stages IIIA and IIIB without pleural effusion) from 1997 to 2002 were identified in Surveillance Epidemiology and End Results-Medicare. Detailed insurance claims were used to characterize treatment modality (none, chemotherapy only, radiotherapy only [XRT-ONLY], or CMT). CMT was further categorized as sequential (CMT-SEQ), or concurrent chemoradiation alone (CMT-ONLY), with induction (CMT-IND), or with consolidation chemotherapy (CMT-CON). Nonparametric models estimated survival effects of treatment regimens, controlling for patient characteristics, including claims-based indicators of performance status. Propensity score analysis adjusted for treatment selection.
Results: Of the 6325 patients, 66% received therapy, with 41% (N = 1745) receiving XRT-ONLY and 45% (N = 1909) receiving CMT (12.5% CMT-SEQ, 35.3% CMT-ONLY, 11.3% CMT-IND, and 20.3% with CMT-CON). CMT had a survival benefit relative to XRT-ONLY (hazard ratio: 0.782, 95% confidence interval: 0.750-0.816; additional 4.4 months median survival; adjusted 10.7% increase in 1-year survival). Relative to CMT-SEQ, concurrent CMT-ONLY was associated with an increased mortality risk, whereas CMT-IND regimens provided a survival benefit (hazard ratio: 0.731, 95% confidence interval: 0.600-0.891; additional 3.8 months; and adjusted 14.4% increase in 1-year survival).
Conclusion: Survival benefits associated with CMT in clinical trials can extend to the elderly in routine care settings. CMT-ONLY is associated with the greatest mortality risk, suggesting that more gradual strategies (CMT-IND) may be more appropriate for the elderly population.
Similar articles
-
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.J Thorac Oncol. 2010 Jan;5(1):82-9. doi: 10.1097/JTO.0b013e3181c09b28. J Thorac Oncol. 2010. PMID: 19884854
-
The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.Clin Lung Cancer. 2012 Jan;13(1):59-67. doi: 10.1016/j.cllc.2011.06.011. Clin Lung Cancer. 2012. PMID: 21856239
-
Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.J Thorac Oncol. 2012 Jul;7(7):1155-63. doi: 10.1097/JTO.0b013e31824fea07. J Thorac Oncol. 2012. PMID: 22617240
-
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. doi: 10.1016/j.athoracsur.2004.04.085. Ann Thorac Surg. 2004. PMID: 15464470 Review.
-
Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.Arch Phys Med Rehabil. 2008 Apr;89(4):595-601. doi: 10.1016/j.apmr.2007.09.042. Arch Phys Med Rehabil. 2008. PMID: 18373987 Review.
Cited by
-
Exploratory Analysis of Survival and Mortality Rates among Older Lung Cancer Patients Utilizing Different Treatment Modalities.Innov Pharm. 2022 Dec 12;13(2):10.24926/iip.v13i2.4346. doi: 10.24926/iip.v13i2.4346. eCollection 2022. Innov Pharm. 2022. PMID: 36654704 Free PMC article.
-
Health care disparities among octogenarians and nonagenarians with stage III lung cancer.Cancer. 2018 Feb 15;124(4):775-784. doi: 10.1002/cncr.31077. Epub 2018 Jan 8. Cancer. 2018. PMID: 29315497 Free PMC article.
-
Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis.Oncologist. 2023 Feb 8;28(2):e92-e102. doi: 10.1093/oncolo/oyac246. Oncologist. 2023. PMID: 36541690 Free PMC article.
-
Clinical and research priorities for combined modality therapy in stage III NSCLC.Lung Cancer Manag. 2016 Apr;5(1):43-50. doi: 10.2217/lmt-2015-0010. Epub 2016 Mar 22. Lung Cancer Manag. 2016. PMID: 30643548 Free PMC article. Review.
-
Challenges in optimizing chemoradiation in locally advanced non small-cell lung cancers in India.South Asian J Cancer. 2013 Oct;2(4):265-71. doi: 10.4103/2278-330X.119893. South Asian J Cancer. 2013. PMID: 24455655 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical